NCT06643819 Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
| NCT ID | NCT06643819 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Condition | Essential Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 324 participants |
| Start Date | 2024-10-14 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 324 participants in total. It began in 2024-10-14 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
Eligibility Criteria
Inclusion Criteria: * Participants who are 19 years old or older. * Participants who have voluntarily decided to participate in this clinical trial and signed ICF. Exclusion Criteria: * Participants with a history of secondary hypertension or suspected secondary hypertension. * Participants with a orthostatic hypotension. * Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period. * Participants with type 1 diabetes or poorly controlled diabetes. * Participants who treated other clinical trial drugs within 4 weeks of screening visit. * Participants with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening * Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug * Participants who are unable to participate in this clinical trial at the discretion of the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06643819 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Essential Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06643819 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 324 participants.
Is NCT06643819 currently recruiting?
Yes, NCT06643819 is actively recruiting participants. Contact the research team at hamki@ckdpharm.com for enrollment information.
Where is the NCT06643819 trial being conducted?
This trial is being conducted at Wŏnju, South Korea.
Who is sponsoring the NCT06643819 clinical trial?
NCT06643819 is sponsored by Chong Kun Dang Pharmaceutical. The trial plans to enroll 324 participants.